Search

Your search keyword '"sufentanil"' showing total 273 results
Start Over Descriptor "sufentanil" Database Gale General OneFile
273 results on '"sufentanil"'

1. Researcher at Department of Anesthesiology Releases New Data on Central Nervous System Agents (Determination of the effective dose of remimazolam combined with sufentanil for inhibiting body movement during surgical abortion: An up-and-down ...)

Subjects
Obesity, Sufentanil, Central nervous system agents, Abortion, Physical fitness, Central nervous system, Health
Abstract

2024 AUG 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on central nervous system agents. According to news [...]

Published
2024

2. Le dragon et le fentanyl La nouvelle guerre de l’opium

Subjects
Opium, Sufentanil
Abstract

Actualité Enquête Le dragon et le fentanyl La nouvelle guerre de l’opium TRAFIC Pour la première fois, les États-Unis ont inscrit la Chine sur la liste noire des principaux pays [...]

Published
2024

3. Effect of different doses of epidural dexmedetomidine on reducing visceral traction reaction for cesarean section: a double-blind randomized controlled trial

Author

Liu, Minghao, Wang, Bin, Prudence, Bizimana, and Chen, Xuezi

Subjects
Cesarean section, Dexmedetomidine, Sufentanil, Clinical trials, Anesthesia, Nausea, Health
Abstract

Purpose This study aimed to evaluate the effect of different doses of epidural dexmedetomidine on reducing visceral traction reaction for cesarean section under epidural anesthesia. Methods Nulliparas were randomly allocated to receive epidural ropivacaine alone (group R) or in combination with dexmedetomidine 0.5 [mu]g/kg (group RD0.5), 0.75 [mu]g/kg (group RD0.75), and 1 [mu]g/kg (group RD1) with 46 nulliparas in each group. The primary outcome was intraoperative visceral traction reaction (graded from 0 to 3, with 0 and 3, respectively, regarded as 'no discomfort in stomach or perineum; no nausea, vomiting or intestinal tympanites' and 'serious visceral pain, nausea and vomiting, intestinal tympanites'). Results Visceral traction reaction was significantly alleviated in group RD0.5, RD0.75, and RD1, respectively, compared to group R while it was comparable among RD groups. Increased Ramsay Sedation Scale and lower incidence of shivering were found in RD groups compared to group R (p < 0.001). None of the primipara has experienced Ramsay Sedation Scale above 4. Higher incidence of thirst was found in group RD0.75 and RD1 compared to group R and RD0.5 (p < 0.001). The Apgar scores at 1 and 5 min of the neonates, onset time to T6 sensory block, maximum sensory block level, the incidence of hypotension, bradycardia and nausea or vomiting were comparable among groups. Conclusion It is suggested that 0.5 [mu]g/kg epidural dexmedetomidine can be used as adjuvant to epidural ropivacaine during cesarean section, because of its alleviating visceral traction reaction, moderate sedating, and reducing shivering without thirst increase., Author(s): Minghao Liu [sup.1], Bin Wang [sup.1], Bizimana Prudence [sup.1], Xuezi Chen [sup.1] Author Affiliations: (1) grid.452206.7, 0000 0004 1758 417X, Department of Anesthesiology, The First Affiliated Hospital of Chongqing [...]

Published
2023
Full Text
View/download PDF

6. Data from University of Witten Update Knowledge in Opioids (Caesarean Delivery: A Narrative Review on the Choice of Neuraxially Administered Opioid and Its Implications for the Multimodal Peripartum Pain Concept)

Subjects
Cesarean section, Sufentanil, Pain -- Care and treatment, Physical fitness, Health
Abstract

2024 MAR 16 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Research findings on opioids are discussed in a new report. According to [...]

Published
2024

7. Cerebral Venous Sinus Thrombosis with Ipsilateral Sinus and Jugular Venous Hypoplasia in Pregnancy

Author

Wang, Jue, Zhou, Qing, and Zhang, He

Subjects
Stroke (Disease), Seizures (Medicine), Levetiracetam, Multiple sclerosis, Blood clot, Sufentanil, Dezocine, Thrombosis, Pregnant women, Health
Abstract

Byline: Jue. Wang, Qing. Zhou, He. Zhang Sir, Cerebral venous thrombosis (CVT) is a rare neurological condition that can occur after a stroke. Headache, seizures, or hemiplegia are common symptoms. [...]

Published
2023

9. XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals’ Sale of its Priority Review Voucher

Subjects
XOMA Corp., Biological products, Sufentanil, Pharmaceutical industry, Banking, finance and accounting industries, Ojemda (Medication)
Abstract

(GlobeNewswire) - XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has received an $8.1 million milestone payment from Viracta Therapeutics, Inc., related to Day One Biopharmaceuticals recent [...]

Published
2024

11. XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO(TM) (clindamycin phosphate) Vaginal Gel 2%

Subjects
Bayer HealthCare AG, XOMA Corp., Sildenafil, Sufentanil, Antibacterial agents, Phosphates, Sexual disorders, Banking, finance and accounting industries, Business, Xaciato (Medication)
Abstract

Organon, a global women's healthcare company, initiated XACIATO(TM) commercial activities in the fourth quarter of 2023 XOMA further expands its late-stage portfolio with synthetic royalty and milestone interests in two [...]

Published
2024

12. XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

Subjects
United States. Food and Drug Administration, XOMA Corp., Gene mutations, Pediatrics, Biological products, Sufentanil, Gliomas -- Drug therapy, Drug approval, Pharmaceutical industry, Banking, finance and accounting industries, Business
Abstract

XOMA is entitled to a mid-single digit royalty on global OJEMDA(TM) sales First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF [...]

Published
2024

13. Provision Of Analgesic, Anti-inflammatory Drugs, Etc

Subjects
Sufentanil, Imipenem, Anti-inflammatory drugs, Business, international
Abstract

Contract awarded for provision of analgesic, anti-inflammatory drugs, etc. by purchasing the medicines described in ii.2, the contracting authority wants to respond to the needs identified within the hospital, because [...]

Published
2024

15. Labor neuraxial analgesia and clinical outcomes

Author

Mazda, Yusuke

Subjects
Medical centers, Bupivacaine, Analgesia, Infants, Sufentanil, Medical colleges, Obstetrics, Health
Abstract

Author(s): Yusuke Mazda [sup.1] Author Affiliations: (1) grid.410802.f, 0000 0001 2216 2631, Department of Obstetric Anesthesiology, Center for Maternal-Fetal and Neonatal Medicine, Saitama Medical Center, Saitama Medical University, , 1981 [...]

Published
2022
Full Text
View/download PDF

16. Anesthetic strategy for obese patients during gastroscopy: deep sedation or conscious sedation? A prospective randomized controlled trial

Author

Kang, Shuai, Lu, Jian, and Zhou, Hong-mei

Subjects
Medical research, Medicine, Experimental, Patient satisfaction, Sufentanil, Propofol, Health
Abstract

Objective This paper aims to compare the incidence of SpO.sub.2 values < 95% and < 90% of the obese patients between conscious sedation and deep sedation and whether conscious sedation was superior to the deep sedation for obese patients during diagnostic gastroscopy. Methods Obese patients undergoing diagnostic gastroscopy were randomly assigned to two different intervention groups: group CS (conscious sedation) or group DS (deep sedation). Group CS patients were managed by conscious sedation [Modified Observer Assessment of Alertness/Sedation (MOAA/S) at 4-5] protocol, and group DS patients were managed by deep sedation (MOAA/S at [less than or equal to] 2) protocol. Propofol and sufentanil (0.1 and 0.05 mg/kg) were, respectively, infused for sedation and analgesia in CS and DS protocols. The primary endpoints were to compare the incidence of SpO.sub.2 values < 95% and < 90% of the patients between the two groups. The incidence of successful sedation, satisfaction scores of patients and endoscopist were assessed as secondary endpoints. Results 115 obese patients (59 in group CS and 56 in group DS) were enrolled in this study. The incidences of SpO.sub.2 < 95% and < 90% in group CS (42.4% and 6.8%) were significantly lower than those in group DS (69.6% and 19.6%, with P = 0.003 and 0.041, respectively). The incidence of successful sedation was similar between groups (86.4% vs 89.3%, P = 0.641). Patient satisfaction scores and endoscopist satisfaction scores were both similar between groups (P = 0.548 and 0.171). Conclusion Conscious sedation with propofol and sufentanil (0.1 mg/kg) reduced the incidence of hypoxic events without affecting gastroscopy procedure and satisfaction compared with the deep sedation for obese patients during diagnostic gastroscopy. Trial registration ChiCTR-1900024894; registration date, July 31, 2019. http://www.chictr.org.cn., Author(s): Shuai Kang [sup.1], Jian Lu [sup.1], Hong-mei Zhou [sup.1] Author Affiliations: (1) grid.411870.b, 0000 0001 0063 8301, Department of Anesthesiology, Second Affiliated Hospital of Jiaxing University, , 314000, Jiaxing, [...]

Published
2021
Full Text
View/download PDF

19. Lp For Cns Narcotic And Psychotropic Substances I

Subjects
Sufentanil, Psychotropic drugs, Business, international
Abstract

Tenders are invited for LP for CNS Narcotic and psychotropic substances I. the subject of the public contract is the regular supply of medicinal products containing the active substance sufentanil [...]

Published
2024

20. FORM 8-K: TALPHERA, INC. Files Current Report (Jan 18, 2024)

Subjects
United States. Securities and Exchange Commission, Securities law, Sufentanil, Stock-exchange, Financial statements, News, opinion and commentary, Securities Exchange Act
Abstract

Washington: TALPHERA, INC., has filed FORM 8-K (Current Report) with the U.S. Securities and Exchange Commission on Jan 18, 2024: UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM [...]

Published
2024

21. Researchers at Fudan University Target Clinical Medicine (A Prospective Randomized Trial of Ropivacaine 5 Mg With Sufentanil 2.5 Mu G As a Test Dose for Detecting Epidural and Intrathecal Injection In Obstetric Patients)

Subjects
Women -- Health aspects, Sufentanil, Obstetrics, Health, Women's issues/gender studies
Abstract

2023 FEB 16 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- New research on Health and Medicine - Clinical Medicine is the subject of a [...]

Published
2023

22. New Clinical Medicine Study Findings Reported from Fudan University Obstetrics and Gynecology Hospital (A Prospective Randomized Trial of Ropivacaine 5 mg with Sufentanil 2.5 mg as a Test Dose for Detecting Epidural and Intrathecal Injection in ...)

Subjects
Women -- Health aspects, Sufentanil, Obstetrics, Health, Women's issues/gender studies
Abstract

2023 JAN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators discuss new findings in clinical medicine. According to news reporting originating from Shanghai, [...]

Published
2023

23. University of Electronic Science and Technology of China (UESTC) Researchers Have Provided New Data on Cesarean Section [The minimum effective concentration (MEC90) of ropivacaine for ultrasound-guided quadratus lumborum block for analgesia ...]

Subjects
Women -- Health aspects, Cesarean section, Analgesia, Sufentanil, Health, Women's issues/gender studies
Abstract

2023 JAN 19 (NewsRx) -- By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators discuss new findings in cesarean section. According to news reporting out of the [...]

Published
2023

24. Second Affiliated Hospital of Army Medical University Researchers Highlight Research in Nephrectomy (Ultrasound-guided erector spinae plane block for perioperative analgesia in patients undergoing laparoscopic nephrectomy surgery: A randomized ...)

Subjects
Laparoscopy, Medical research, Medicine, Experimental, Laparoscopic surgery, Analgesia, Dexmedetomidine, Sufentanil, Clinical trials, Remifentanil, Health
Abstract

2024 MAR 11 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Investigators discuss new findings in nephrectomy. According to news originating from Chongqing, People's Republic [...]

Published
2024

25. Studies in the Area of Postpartum Depression Reported from General Hospital of the Chinese People's Liberation Army (Efficacy of Esketamine for the Treatment of Postpartum Depression and Pain Control Following Cesarean Section: a Randomized, ...)

Subjects
Medical research, Medicine, Experimental, Cesarean section, Sufentanil, Pain -- Care and treatment, Postpartum depression -- Drug therapy, Health, Psychology and mental health
Abstract

2024 MAR 4 (NewsRx) -- By a News Reporter-Staff News Editor at Mental Health Weekly Digest -- Current study results on Mental Health Diseases and Conditions - Postpartum Depression have [...]

Published
2024

26. Sufentanil, Inj, 50 Mcg|ml, 5 Ml, 1 Lag

Subjects
Sufentanil, Business, international
Abstract

Contract awarded: Sufentanil, inj, 50 mcg/ml, 5 ml, 1 lag Purchase of medicinal products iii/2022 Contractor name : PHOENIX LKRENSK VELKOOBCHOD, S.R.O. Contractor address : K provn 945/7 Implementing agency [...]

Published
2023

28. AcelRx's Dsuvia featured in presentation of 324 plastic surgery procedures

Subjects
Sufentanil, Surgery, Plastic, Business, News, opinion and commentary, Dsuvia (Medication)
Abstract

AcelRx Pharmaceuticals announced that an abstract was presented on October 28th at Plastic Surgery The Meeting 2022, held October 27-30, in Boston, MA. The study, conducted in 324 patients undergoing [...]

Published
2022

29. AcelRx reports results from Sublingual Sufentanil trial

Subjects
Sufentanil, Business, News, opinion and commentary
Abstract

AcelRx Pharmaceuticals announced that the results of a 190-patient, investigator-initiated trial conducted at Brigham and Women's Hospital in Boston, MA, entitled, 'The Impact of Sublingual Sufentanil on Postoperative Pain Control [...]

Published
2022

30. Analgesia as part of the orotracheal intubation induction sequence

Author

Tejado, Sandra, Naharro, Antonio, and Alcántara, Sara

Subjects
Alfentanil, Sufentanil, Health care industry
Abstract

Author(s): Sandra Tejado [sup.1], Antonio Naharro [sup.2], Sara Alcántara [sup.1] Author Affiliations: (1) grid.73221.35, 0000 0004 1767 8416, Puerta de Hierro University Hospital of Majadahonda: Hospital Universitario Puerta de Hierro [...]

Published
2022
Full Text
View/download PDF

31. FDA Modifies REMS Requirements for Opioid Analgesic Dsuvia

Author

Park, Brian

Subjects
United States. Food and Drug Administration, Sufentanil, Health, Dsuvia (Medication)
Abstract

The Risk Evaluation and Mitigation Strategies (REMS) requirements for Dsuvia® (sufentanil) have recently been modified by the Food and Drug Administration (FDA) with regard to health care setting audits. The [...]

Published
2022

32. AcelRx announces publication from sufentanil trial

Subjects
Sufentanil, Surgery, Plastic, Business, News, opinion and commentary
Abstract

AcelRx Pharmaceuticals announced the publication of clinical data from an investigator-initiated trial in patients undergoing lengthy plastic surgery procedures performed under general anesthesia, where use of a single sufentanil sublingual [...]

Published
2022

33. AcelRx's Dsuvia shows pain management efficacy and safety in presentation

Subjects
Sufentanil, Pain -- Care and treatment, Business, News, opinion and commentary, Dsuvia (Medication)
Abstract

AcelRx announced a summary of results from a podium presentation on Dsuvia - sufentanil sublingual tablet - presented at the annual meeting of The Aesthetic Society. Some of the data [...]

Published
2022

34. AcelRx's sufentanil tablet shows pain reduction efficacy in microneedling

Subjects
Sufentanil, Pain -- Care and treatment, Business, News, opinion and commentary
Abstract

AcelRx announced the publication of a study evaluating the use of a sufentanil sublingual tablet 30 mcg for management of pain of radiofrequency microneedling of the face or abdomen. The [...]

Published
2022

35. AcelRx Pharmaceuticals Announces Closing of Divestment of DSUVIA to Alora Pharmaceuticals

Subjects
Sufentanil, Pharmaceutical industry, Business, News, opinion and commentary, Alora (Medication), Dsuvia (Medication)
Abstract

In connection with closing, AcelRx received approximately $2.7 million from Alora Pharmaceuticals and Aguettant AcelRx announces full repayment of its senior loan with Oxford Finance HAYWARD, Calif., April 5, 2023 [...]

Published
2023

36. mother. doctor. wife. addict

Author

Adler, Kayla Webley

Subjects
Physicians, Sufentanil, Opioids, Death, Husband-wife relations, Overdose, Fashion and beauty, Women's issues/gender studies
Abstract

Opioids have become a fullblown national crisis of epidemic proportions, killing 130 people each day. Drug overdose is now the number-one cause of death for Americans under 50. One doctor [...]

Published
2019

37. Reports from North Sichuan Medical College Describe Recent Advances in Gastric Cancer (Comparing the Effectiveness of S-ketamine Combined With Sufentanil Versus Sufentanil Alone for Postoperative Pain Management In Elderly Patients Undergoing ...)

Subjects
Aged patients, Sufentanil, Stomach cancer, Medical colleges, Pain -- Care and treatment, Cancer, Pain, Postoperative, Business, Health, Health care industry
Abstract

2023 JUL 11 (NewsRx) -- By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Gastric Cancer. According to news reporting originating from [...]

Published
2023

39. AcelRx Pharmaceuticals Announces Divestment of DSUVIA to Alora Pharmaceuticals

Subjects
United States. Department of Defense, Sufentanil, Business, News, opinion and commentary, Alora (Medication), Dsuvia (Medication)
Abstract

Agreement with Alora Pharmaceuticals provides AcelRx with 15% royalties on commercial sales, 75% royalties on Department of Defense (DoD) sales, up to $116.5 million in potential sales-based milestone payments, and [...]

Published
2023

40. Delivery Of Medicinal Products, Medical Devices And Cosmetics Specified In 50 Packages

Subjects
Medical equipment, Sufentanil, Remifentanil, Physiological apparatus, Business, international
Abstract

Contract notice: delivery of medicinal products, medical devices and cosmetics specified in 50 packages. The subject of the contract is the supply of medicinal products, medical devices and cosmetics specified [...]

Published
2023

41. AcelRx reports results from study of sufentanil sublingual tablet 30 mcg

Subjects
Sufentanil, Surgery, Plastic, Business, News, opinion and commentary
Abstract

AcelRx Pharmaceuticals announced the results of a study evaluating sufentanil sublingual tablet 30 mcg for outpatient plastic surgery that was presented during the Miami Cosmetic Surgery conference on Friday, August [...]

Published
2021

43. Oculocardiac reflex in an anophthalmic eye

Author

Jain, Aditi, Mehta, Aditi, Singh, Usha, and Saini, Vikas

Subjects
Sufentanil, Surgery, Retinoblastoma, Health
Abstract

Byline: Aditi. Jain, Aditi. Mehta, Usha. Singh, Vikas. Saini Sir, Oculocardiac reflex (OCR) is one of the most notorious complications associated with ophthalmic surgeries. We would like to report a [...]

Published
2020

44. Supplies Of Medicinal Product - Sufentanil

Subjects
Sufentanil, Business, international
Abstract

Tenders are invited for Supplies of medicinal product - Sufentanil DBID: 29961 System number: P22V00004618 Start date: 28/12/2022 Bid submission by: 06/01/2023 10:00 Title, type of public contract and description [...]

Published
2022

46. AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine

Subjects
Sufentanil, Pain -- Care and treatment, Pain, Postoperative -- Care and treatment, Company business management, General interest, News, opinion and commentary
Abstract

HAYWARD: AcelRx Pharmaceuticals, Inc. has issued the following news release: AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for [...]

Published
2022

47. AcelRx Pharma gains 8% on positive data from post-operative pain management therapy

Subjects
Sufentanil, Pain -- Care and treatment, Pain, Postoperative -- Care and treatment, Company business management, General interest, News, opinion and commentary
Abstract

Shares of AcelRx Pharma (NASDAQ:ACRX) traded higher after its sublingual sufentanil tablets for postoperative pain management showed lower pain scores, fewer rescue doses, and shorter hospital stays in patients compared [...]

Published
2022

48. AcelRx Pharmaceuticals Announces European Peer-Reviewed Publication Supporting the Benefits of Sublingual Sufentanil Tablets For Post-Operative Pain Management in the Journal of Clinical Medicine

Subjects
Medical research, Medicine, Experimental, Sufentanil, Pain -- Care and treatment, Pain, Postoperative -- Care and treatment, Company business management, Business, News, opinion and commentary, Dsuvia (Medication)
Abstract

Patients reported lower pain scores, required fewer rescue doses and had a shorter hospital stay than patients receiving continuous femoral nerve block This study of patients following knee replacement surgery [...]

Published
2022

50. AcelRx Pharmaceuticals Announces Presentation of a Large Cohort of Complex Plastic Surgery Procedures Performed with DSUVIA at Plastic Surgery The Meeting 2022

Subjects
Sufentanil, Surgery, Plastic, General interest, News, opinion and commentary, Dsuvia (Medication)
Abstract

HAYWARD: AcelRx Pharmaceuticals, Inc. has issued the following news release: AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for [...]

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results